- SAN711 is a first-in-class, highly selective GABAA-α3 positive allosteric modulator
- Targeting initiation of Phase 2 study of SAN711 for the treatment of essential tremor in 2026
https://www.businesswire.com/news/home/20241126842206/en/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.